| Date | Title | Description | |
|---|---|---|---|
| 27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
| 08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
| 26 Jul 2023 | On P&L | The Company releases the press release related to the first half 2023 financial results | Download |
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 27 Jul 2020 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors. | Download |
| 27 Jul 2020 | On business and financial situation | ROVI releases the 2020 First Half Results presentation | Download |
| 02 Jul 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2020 | Download |
| 13 May 2020 | On business and financial situation | ROVI releases the presentation related to the first quarter 2020 financial results | Download |
| 13 May 2020 | Interim Management Report | The company releases the press release related to the 2020 first quarter financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |